Synergistic action of curcumin and cisplatin on spinel ferrite/hierarchical MCM-41 nanocomposite against MCF-7, HeLa and HCT 116 cancer cell line

Abstract Background Platinum-based drugs are widely used in cancer therapy, but are known for toxic side effects and resistance. Combinational drug delivery represents an effective chemotherapeutic strategy, but often leads to an increased toxicity. Aim of this study is to test the co-delivery of ci...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	B. Rabindran Jermy, D. Almohazey, W. A. Alamoudi, R. M. Palanivel, Nora AlSudairi, H. Dafalla, A. A. Almofleh, T. M. Alfareed, Vijaya Ravinayagam
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Multifunctional Curcumin Coating, cisplatin MCM-41 Nanotherapeutics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9062f3ab363e478fbdc18cdc98a53faf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9062f3ab363e478fbdc18cdc98a53faf
record_format	dspace
spelling	oai:doaj.org-article:9062f3ab363e478fbdc18cdc98a53faf2021-11-28T12:09:49ZSynergistic action of curcumin and cisplatin on spinel ferrite/hierarchical MCM-41 nanocomposite against MCF-7, HeLa and HCT 116 cancer cell line10.1186/s12645-021-00106-71868-69581868-6966https://doaj.org/article/9062f3ab363e478fbdc18cdc98a53faf2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12645-021-00106-7https://doaj.org/toc/1868-6958https://doaj.org/toc/1868-6966Abstract Background Platinum-based drugs are widely used in cancer therapy, but are known for toxic side effects and resistance. Combinational drug delivery represents an effective chemotherapeutic strategy, but often leads to an increased toxicity. Aim of this study is to test the co-delivery of cisplatin with natural antioxidants on hierarchial porous large surface area hexagonal nanocarriers for synergistic action. Results A series of structured mesoporous materials were impregnated with magnetic spinel ferrite (30% CuFe2O4) and then coated with curcumin (25% wt/wt). Mesosilicalite and MCM-41 with high curcumin release abilities were functionalized with cisplatin (5% wt/wt) for synergistic effect of combinational drugs. The cytotoxic efficiency of our nanocomposites was tested on cell viability of MCF7 (human breast cancer), human cervical cancer (HeLa), colorectal cancer (HCT116), and HFF (human foreskin fibroblasts) cell lines using the MTT cell viability assay. At a concentration of 0.1 mg/ml, CuFe2O4/mesosilicalite/curcumin/cisplatin resulted in 89.53% reduction in viability in MCF7, 94.03% in HeLa, 64% in HCT116 and 87% in HFF; whereas, CuFe2O4/MCM-41/curcumin/cisplatin resulted in 76% reduction in viability in MCF7, 64.46% in HeLa, 64% in HCT116 and 24% in HFF. The EC50 for CuFe2O4/mesosilicalite/curcumin/cisplatin was 81.23 µg/ml in MCF7, 47.55 µg/ml in HeLa, 48.96 µg/ml in HCT116 and 76.83 µg/ml in HFF. The EC50 for CuFe2O4/MCM-41/curcumin/cisplatin was 72.51 µg/ml in MCF7, 58.6 µg/ml in HeLa, 62.58 µg/ml in HCT116 and 154.2 µg/ml in HFF. Furthermore, cells treated with both nanocomposites had a high number of cleaved Caspase 3-positive cells suggesting that the reduction in cell viability was triggered by activating the apoptotic signaling pathway. Conclusion Our results show that CuFe2O4/MCM-41/curcumin/cisplatin is a better candidate for combinational drug therapy due to its lowest EC50 value and the wider difference in EC50 (a fold change) between cancerous and non-cancerous cell line.B. Rabindran JermyD. AlmohazeyW. A. AlamoudiR. M. PalanivelNora AlSudairiH. DafallaA. A. AlmoflehT. M. AlfareedVijaya RavinayagamBMCarticleMultifunctionalCurcuminCoating, cisplatinMCM-41NanotherapeuticsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Nanotechnology, Vol 12, Iss 1, Pp 1-21 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Multifunctional Curcumin Coating, cisplatin MCM-41 Nanotherapeutics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Multifunctional Curcumin Coating, cisplatin MCM-41 Nanotherapeutics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 B. Rabindran Jermy D. Almohazey W. A. Alamoudi R. M. Palanivel Nora AlSudairi H. Dafalla A. A. Almofleh T. M. Alfareed Vijaya Ravinayagam Synergistic action of curcumin and cisplatin on spinel ferrite/hierarchical MCM-41 nanocomposite against MCF-7, HeLa and HCT 116 cancer cell line
description	Abstract Background Platinum-based drugs are widely used in cancer therapy, but are known for toxic side effects and resistance. Combinational drug delivery represents an effective chemotherapeutic strategy, but often leads to an increased toxicity. Aim of this study is to test the co-delivery of cisplatin with natural antioxidants on hierarchial porous large surface area hexagonal nanocarriers for synergistic action. Results A series of structured mesoporous materials were impregnated with magnetic spinel ferrite (30% CuFe2O4) and then coated with curcumin (25% wt/wt). Mesosilicalite and MCM-41 with high curcumin release abilities were functionalized with cisplatin (5% wt/wt) for synergistic effect of combinational drugs. The cytotoxic efficiency of our nanocomposites was tested on cell viability of MCF7 (human breast cancer), human cervical cancer (HeLa), colorectal cancer (HCT116), and HFF (human foreskin fibroblasts) cell lines using the MTT cell viability assay. At a concentration of 0.1 mg/ml, CuFe2O4/mesosilicalite/curcumin/cisplatin resulted in 89.53% reduction in viability in MCF7, 94.03% in HeLa, 64% in HCT116 and 87% in HFF; whereas, CuFe2O4/MCM-41/curcumin/cisplatin resulted in 76% reduction in viability in MCF7, 64.46% in HeLa, 64% in HCT116 and 24% in HFF. The EC50 for CuFe2O4/mesosilicalite/curcumin/cisplatin was 81.23 µg/ml in MCF7, 47.55 µg/ml in HeLa, 48.96 µg/ml in HCT116 and 76.83 µg/ml in HFF. The EC50 for CuFe2O4/MCM-41/curcumin/cisplatin was 72.51 µg/ml in MCF7, 58.6 µg/ml in HeLa, 62.58 µg/ml in HCT116 and 154.2 µg/ml in HFF. Furthermore, cells treated with both nanocomposites had a high number of cleaved Caspase 3-positive cells suggesting that the reduction in cell viability was triggered by activating the apoptotic signaling pathway. Conclusion Our results show that CuFe2O4/MCM-41/curcumin/cisplatin is a better candidate for combinational drug therapy due to its lowest EC50 value and the wider difference in EC50 (a fold change) between cancerous and non-cancerous cell line.
format	article
author	B. Rabindran Jermy D. Almohazey W. A. Alamoudi R. M. Palanivel Nora AlSudairi H. Dafalla A. A. Almofleh T. M. Alfareed Vijaya Ravinayagam
author_facet	B. Rabindran Jermy D. Almohazey W. A. Alamoudi R. M. Palanivel Nora AlSudairi H. Dafalla A. A. Almofleh T. M. Alfareed Vijaya Ravinayagam
author_sort	B. Rabindran Jermy
title	Synergistic action of curcumin and cisplatin on spinel ferrite/hierarchical MCM-41 nanocomposite against MCF-7, HeLa and HCT 116 cancer cell line
title_short	Synergistic action of curcumin and cisplatin on spinel ferrite/hierarchical MCM-41 nanocomposite against MCF-7, HeLa and HCT 116 cancer cell line
title_full	Synergistic action of curcumin and cisplatin on spinel ferrite/hierarchical MCM-41 nanocomposite against MCF-7, HeLa and HCT 116 cancer cell line
title_fullStr	Synergistic action of curcumin and cisplatin on spinel ferrite/hierarchical MCM-41 nanocomposite against MCF-7, HeLa and HCT 116 cancer cell line
title_full_unstemmed	Synergistic action of curcumin and cisplatin on spinel ferrite/hierarchical MCM-41 nanocomposite against MCF-7, HeLa and HCT 116 cancer cell line
title_sort	synergistic action of curcumin and cisplatin on spinel ferrite/hierarchical mcm-41 nanocomposite against mcf-7, hela and hct 116 cancer cell line
publisher	BMC
publishDate	2021
url	https://doaj.org/article/9062f3ab363e478fbdc18cdc98a53faf
work_keys_str_mv	AT brabindranjermy synergisticactionofcurcuminandcisplatinonspinelferritehierarchicalmcm41nanocompositeagainstmcf7helaandhct116cancercellline AT dalmohazey synergisticactionofcurcuminandcisplatinonspinelferritehierarchicalmcm41nanocompositeagainstmcf7helaandhct116cancercellline AT waalamoudi synergisticactionofcurcuminandcisplatinonspinelferritehierarchicalmcm41nanocompositeagainstmcf7helaandhct116cancercellline AT rmpalanivel synergisticactionofcurcuminandcisplatinonspinelferritehierarchicalmcm41nanocompositeagainstmcf7helaandhct116cancercellline AT noraalsudairi synergisticactionofcurcuminandcisplatinonspinelferritehierarchicalmcm41nanocompositeagainstmcf7helaandhct116cancercellline AT hdafalla synergisticactionofcurcuminandcisplatinonspinelferritehierarchicalmcm41nanocompositeagainstmcf7helaandhct116cancercellline AT aaalmofleh synergisticactionofcurcuminandcisplatinonspinelferritehierarchicalmcm41nanocompositeagainstmcf7helaandhct116cancercellline AT tmalfareed synergisticactionofcurcuminandcisplatinonspinelferritehierarchicalmcm41nanocompositeagainstmcf7helaandhct116cancercellline AT vijayaravinayagam synergisticactionofcurcuminandcisplatinonspinelferritehierarchicalmcm41nanocompositeagainstmcf7helaandhct116cancercellline
_version_	1718408153897369600

Synergistic action of curcumin and cisplatin on spinel ferrite/hierarchical MCM-41 nanocomposite against MCF-7, HeLa and HCT 116 cancer cell line

Ejemplares similares